No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Smith+Nephew Announces Digital Surgery & Robotics Innovation Center in Europe

Editor: What To Know

  • The new innovation center will bring healthcare professionals from Europe, the Middle East, and Africa together with Smith+Nephew’s R&D and medical education teams to explore digital surgery and robotics techniques and technologies.
  • It joins Smith+Nephew’s recently opened robotics R&D and medical education facility in Pittsburgh, US in offering a unique collaborative approach to customer experience and product development.
  • SNN), the global medical technology business, is proud to announce the creation of a purpose-built digital surgery and robotics innovation center, based in Munich, Germany.

Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, is proud to announce the creation of a purpose-built digital surgery and robotics innovation center, based in Munich, Germany.

The new innovation center will bring healthcare professionals from Europe, the Middle East, and Africa together with Smith+Nephew’s R&D and medical education teams to explore digital surgery and robotics techniques and technologies. At the heart of this will be Real Intelligence, Smith+Nephew’s digital ecosystem, including the new state-of-the-art robotics-assisted surgical system CORI™.

The center will feature a dedicated medical education facility, where surgeons can refine techniques and experience the latest technology through hands-on learning and immersive simulation technology.

The center will also home Smith+Nephew’s digital surgery and robotics R+D team, enabling them to collaborate with surgeons, scientists and engineers, driving innovation that meets unmet clinical needs. Many of this team joined Smith+Nephew from Brainlab under the terms of a collaboration agreement announced in 2019.

Smith+Nephew EMEA President, Peter Coenen said, “We are excited to be announcing this state-of-the-art facility focused on the development and delivery of digital surgery technologies and techniques. We look forward to sharing our plans as we progress our technology vision, and to welcoming customers to experience a new approach to medical education when we open next year.”

The new facility, which is expected to open late 2022, will be situated at the Rhythm complex at Kustermann Park, in central Munich. It joins Smith+Nephew’s recently opened robotics R&D and medical education facility in Pittsburgh, US in offering a unique collaborative approach to customer experience and product development.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy